<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00444379</url>
  </required_header>
  <id_info>
    <org_study_id>NIH/NCI Grant #: R01 CA119903</org_study_id>
    <nct_id>NCT00444379</nct_id>
  </id_info>
  <brief_title>Anti-Retrovirals for Kaposi's Sarcoma</brief_title>
  <acronym>ARKS</acronym>
  <official_title>A Randomized Comparison of Protease Inhibitor-based Versus Non-nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy for Initial Treatment of Individuals With AIDS-related Kaposi's Sarcoma in Sub-Saharan Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine whether a protease inhibitor-based&#xD;
      antiretroviral regimen is more efficacious than a non-nucleoside reverse transcriptase&#xD;
      inhibitor-based antiretroviral regimen in promoting the regression of KS tumor burden in&#xD;
      persons with AIDS-related KS in Africa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With the advent of the HIV epidemic, Kaposi's sarcoma (KS) is now the most common adult&#xD;
      cancer in many parts of sub-Saharan Africa. In HIV-infected patients with KS in developed&#xD;
      settings, the initiation of highly active anti-retroviral therapy (HAART) has been associated&#xD;
      with regression of the tumor, in many but not all cases, even in the absence of conventional&#xD;
      chemotherapy. However, it is not known which specific antiretroviral drugs or regimens are&#xD;
      critical to convey HAART's anti-KS effect. In particular, it is not known whether the anti-KS&#xD;
      effects of protease inhibitors (PI) in vitro and in animal models translate into improved&#xD;
      clinical outcomes as compared to non-PI-based HAART regimens. To address this, we will&#xD;
      determine whether a PI-based HAART regimen (lopinavir/ritonavir plus emtricitabine/tenofovir)&#xD;
      is superior to a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART regimen&#xD;
      (efavirenz plus emtricitabine/tenofovir) in promoting the regression of KS tumor burden in&#xD;
      persons with AIDS-related KS in sub-Saharan Africa. We will enroll 224 patients with&#xD;
      AIDS-related KS in Kampala, Uganda, randomly assign them to either a PI-based HAART or an&#xD;
      NNRTI-based HAART regimen, and observe them for one year to determine the response in their&#xD;
      KS to therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blinded assessment of the change in the burden of KS lesions</measure>
    <description>survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4+ T cell count and HIV plasma HIV RNA levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KSHV DNA levels in saliva and blood</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral and cellular KSHV immune response markers</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life assessment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Kaposi's sarcoma-associated Immune Reconstitution Inflammatory Syndrome (KS-IRIS)</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Kaposi's Sarcoma</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>PI-based HAART regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PI-based HAART regimen (lopinavir/ritonavir plus emtricitabine/tenofovir)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-nucleoside reverse transcriptase inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART regimen (efavirenz plus emtricitabine/tenofovir)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir</intervention_name>
    <description>Lopinavir/ritonavir 200/50mg plus Emtricitabine/Tenofovir 200/300mg versus Efavirenz 600mg plus Emtricitabine/Tenofovir 200/300mg</description>
    <arm_group_label>PI-based HAART regimen</arm_group_label>
    <arm_group_label>non-nucleoside reverse transcriptase inhibitor</arm_group_label>
    <other_name>Lopinavir/ritonavir Aluvia (ALUABT)</other_name>
    <other_name>Efavirenz Stocrin (EFVBMM)</other_name>
    <other_name>Emtricitabine/Tenofovir Truvada (TRUGLD)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  No prior antiretroviral therapy of any duration, including prior use to prevent&#xD;
             perinatal transmission within prior six months.&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy for KS&#xD;
&#xD;
          -  Presence of Kaposi's sarcoma, documented by biopsy by the Pathology Department at&#xD;
             Mulago Hospital, with at least one mucocutaneous lesion (including oral or genital&#xD;
             mucosal lesions), each at least 0.6 x 0.6 cm in perpendicular diameters.&#xD;
&#xD;
          -  Laboratory values obtained within 21 days prior to randomization: absolute neutrophil&#xD;
             count equal to or more than 1000/mm3; hemoglobin &gt; 9.0 g/dL; platelet count &gt;&#xD;
             50,000/mm3; creatinine &lt; 2 times upper limit of normal (ULN); aspartate&#xD;
             aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 5 times ULN; and alkaline&#xD;
             phosphatase and total bilirubin &lt; 2 times ULN.&#xD;
&#xD;
          -  In women, negative urine pregnancy test within 28 days of randomization and just&#xD;
             before randomization.&#xD;
&#xD;
          -  If a woman of child-bearing potential (i.e., not yet reached menopause or undergone&#xD;
             hysterectomy, bilateral oophorectomy, or tubal ligation), must be willing to use at&#xD;
             least two of the following methods of contraception, to be provided by the study:&#xD;
             condoms (male or female), IUD, or hormone-based therapy, e.g., contraceptive pills,&#xD;
             Norplant or Depo-Provera.&#xD;
&#xD;
          -  Candidate currently resides within Uganda and does not intend to relocate away from&#xD;
             current geographical area of residence for the duration of study participation.&#xD;
&#xD;
          -  Karnofsky performance score of 70 or more&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extensive degree of mucocutaneous KS, which would typically require chemotherapy or&#xD;
             radiotherapy. This is defined by any of the following:&#xD;
&#xD;
               -  One or more bulky cutaneous lesions, defined as at least 5.0 cm in greatest&#xD;
                  diameter across the surface of the skin and at least 3 cm in height&#xD;
&#xD;
               -  One or more mucocutaneous lesions exhibiting ulceration&#xD;
&#xD;
               -  One or more oral lesions that interfere with swallowing&#xD;
&#xD;
          -  Suggestion of pulmonary or gastrointestinal visceral KS, as evidenced by any of the&#xD;
             following:&#xD;
&#xD;
               -  Abnormal chest x-ray within 21 days prior to randomization which is otherwise&#xD;
                  unexplained, unless the x-ray is unchanged compared with at least 60 days earlier&#xD;
&#xD;
               -  Positive occult blood stool testing within 21 days prior to randomization or&#xD;
                  history of overt bleeding from the mouth or rectum in the 21 days prior to&#xD;
                  randomization&#xD;
&#xD;
          -  Facial lymphedema or lymphedema in any other body region which causes symptoms (e.g.,&#xD;
             pain) or functional disability (e.g., any less than 85% active range of motion in a&#xD;
             large joint)&#xD;
&#xD;
          -  Evidence of currently active, untreated opportunistic infection or malignancy (not&#xD;
             including Kaposi's sarcoma); or unexplained temperature which is &gt; 38.5 degrees C&#xD;
&#xD;
          -  Use of drugs, within the prior 28 days, contraindicated while taking&#xD;
             lopinavir/ritonavir or efavirenz because of effects on the cytochrome P450 system.&#xD;
             These include propafenone, astemizole, terfenadine, rifampin, rifapentine, ergot&#xD;
             derivatives, cisapride, lovastatin, simvastatin, pimozide, midazolam, and triazolam.&#xD;
&#xD;
          -  Active drug or alcohol use that, in the investigators' opinion, would interfere with&#xD;
             study participation&#xD;
&#xD;
          -  Breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Jeffrey N Martin, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Edward K Mbidde, MBChB, MMed</last_name>
    <role>Principal Investigator</role>
    <affiliation>MRC/UVRI and LSHTM Uganda Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Infectious Diseases Institute, Mulago Hospital</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/kaposissarcoma.html</url>
    <description>Medline Plus- Health Information</description>
  </link>
  <link>
    <url>http://info.cancerresearchuk.org</url>
    <description>UK cancer research</description>
  </link>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>March 6, 2007</study_first_submitted>
  <study_first_submitted_qc>March 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2007</study_first_posted>
  <last_update_submitted>August 19, 2014</last_update_submitted>
  <last_update_submitted_qc>August 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kaposi's sarcoma</keyword>
  <keyword>KSHV</keyword>
  <keyword>AIDS</keyword>
  <keyword>HHV-8</keyword>
  <keyword>treatment naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

